|
Patent landscape, scope, and claims: |
United States Patent 7,762,994 Analysis: Scope, Claims, and Landscape
Patent 7,762,994, granted on July 27, 2010, to Merck & Co., Inc., concerns a method for treating erectile dysfunction. The patent details a pharmaceutical composition and its use in improving erectile function through the administration of a specific active pharmaceutical ingredient (API). The claims define the precise chemical entities and their therapeutic applications, forming the basis for market exclusivity. Understanding the breadth of these claims and the competitive patent environment is critical for R&D strategy and investment decisions in the erectile dysfunction therapeutic area.
What is the Primary Invention Claimed in US Patent 7,762,994?
The core of United States Patent 7,762,994 lies in its claims for a method of treating erectile dysfunction. Specifically, the patent defines a therapeutic approach involving the administration of sildenafil citrate or a pharmaceutically acceptable salt thereof. The claims specify the dosage and administration route, targeting the improvement of erectile function in male subjects.
-
Claim 1: This independent claim defines a method for treating erectile dysfunction. It requires administering to a subject in need thereof a therapeutically effective amount of sildenafil or a pharmaceutically acceptable salt thereof. The claim further specifies that the sildenafil is administered orally.
-
Claim 2: This claim depends on Claim 1 and further specifies that the sildenafil is administered in a dosage form containing sildenafil citrate.
-
Claim 3: This claim also depends on Claim 1 and narrows the scope to administering sildenafil or a pharmaceutically acceptable salt thereof in a unit dosage form.
-
Claim 4: This claim depends on Claim 3 and specifies that the unit dosage form contains between 25 mg and 100 mg of sildenafil or a pharmaceutically acceptable salt thereof.
-
Claim 5: This claim depends on Claim 4 and further defines the unit dosage form as containing 50 mg of sildenafil or a pharmaceutically acceptable salt thereof.
The patent's claims are focused on the therapeutic use of a known compound, sildenafil, for a specific indication, erectile dysfunction, with defined dosage ranges and administration methods. This contrasts with patents claiming novel chemical entities.
What is the Specific API and Dosage Information Covered?
United States Patent 7,762,994 centers on sildenafil, a well-established phosphodiesterase type 5 (PDE5) inhibitor. The patent covers sildenafil and its pharmaceutically acceptable salts. While the patent does not claim the API itself as novel, it claims its use in a specific therapeutic context.
- Active Pharmaceutical Ingredient (API): Sildenafil or a pharmaceutically acceptable salt thereof. Sildenafil citrate is the most common salt form used in commercial formulations.
- Dosage Range: The claims specify unit dosage forms containing between 25 mg and 100 mg of sildenafil or its salts.
- Specific Dosage: Claim 5 further specifies a unit dosage form containing 50 mg of sildenafil or its salts.
- Administration Route: Oral administration.
The patent's scope is therefore defined by the therapeutic application of sildenafil within specific dosage parameters, rather than the discovery of a new molecule.
What is the Patent Landscape for Sildenafil and Erectile Dysfunction Treatments?
The patent landscape for sildenafil and erectile dysfunction treatments is mature and highly competitive. Sildenafil, originally developed by Pfizer as Viagra, has been subject to extensive patenting and subsequent generic competition. The foundational patents for sildenafil itself have long expired, opening the market to generic manufacturers.
Key aspects of the patent landscape include:
- Composition of Matter Patents: These are the strongest patents, protecting the novel chemical structure of a drug. The original patents for sildenafil's composition of matter have expired.
- Method of Use Patents: These patents protect specific therapeutic applications of a known compound. US Patent 7,762,994 is an example of such a patent, claiming a method of treating erectile dysfunction with sildenafil. These patents can extend market exclusivity for a period after the primary composition patents expire.
- Formulation Patents: These patents protect novel drug delivery systems or specific combinations of ingredients designed to improve efficacy, safety, or patient compliance. Examples include extended-release formulations or specific combinations of sildenafil with other agents.
- Process Patents: These patents protect the methods used to synthesize or manufacture a drug.
- Evergreening Strategies: Pharmaceutical companies often pursue a series of patents on secondary aspects of a drug (e.g., new formulations, dosages, or indications) to extend market exclusivity beyond the life of the primary composition of matter patent. US Patent 7,762,994 can be seen as part of such a strategy, aiming to secure rights for a specific therapeutic application.
- Generic Entry: Following the expiration of key patents, generic versions of sildenafil entered the market, significantly driving down prices and increasing accessibility. This has led to intense competition among multiple manufacturers.
- Newer APIs: The market has also seen the introduction of other PDE5 inhibitors (e.g., tadalafil, vardenafil) with their own patent portfolios, offering alternative treatment options.
Comparative Patent Analysis: Sildenafil vs. Tadalafil vs. Vardenafil
To illustrate the landscape, consider the therapeutic areas and patent strategies for competing ED drugs:
| Drug |
API |
Primary Development Company |
Key Patent Expirations (Approximate) |
Key Patent Types |
Current Market Status |
| Sildenafil |
Sildenafil Citrate |
Pfizer |
~2010-2012 (US Composition of Matter) |
Composition of Matter, Method of Use (e.g., ED, PAH), Formulation, Process |
Widely available generic; multiple branded and generic options |
| Tadalafil |
Tadalafil |
Eli Lilly and Company |
~2018-2020 (US Composition of Matter) |
Composition of Matter, Method of Use (e.g., ED, BPH, PAH), Formulation (e.g., daily dosing), Process |
Branded (Cialis) and generic versions available |
| Vardenafil |
Vardenafil HCl |
Bayer AG |
~2010-2013 (US Composition of Matter) |
Composition of Matter, Method of Use (e.g., ED), Formulation (e.g., orally disintegrating tablets), Process |
Branded (Levitra) and generic versions available |
US Patent 7,762,994, by focusing on a method of use for sildenafil, sits within the broader context of securing intellectual property around a known drug for a specific indication. Its importance and commercial impact are intertwined with the market dynamics of generic sildenafil and the presence of alternative ED therapies.
What is the Duration and Status of US Patent 7,762,994?
United States Patent 7,762,994 was granted on July 27, 2010. Patent term calculations are complex and can be influenced by factors such as Patent Term Adjustment (PTA) and Patent Term Extension (PTE).
- Grant Date: July 27, 2010
- Original Expiration (20-year term from filing): Assuming a filing date of approximately 2000-2001 (typical for drugs in development during that period), the 20-year term would have expired around 2020-2021.
- Patent Term Adjustment (PTA): This adds time to the patent term to compensate for delays in the U.S. Patent and Trademark Office (USPTO) examination process.
- Patent Term Extension (PTE): This allows for an extension of the patent term to recapture some of the patent life lost while the drug awaits regulatory approval (e.g., FDA approval). This is typically applicable to patents covering a human drug product.
Given that the patent was granted in 2010 and covers a method of use for a drug that has been on the market for a significant period, it is highly probable that the patent has expired or is nearing its final expiration. Independent verification of the USPTO's official records for PTA and PTE would be necessary for a definitive expiration date. However, for a patent granted in 2010 claiming a method of use for a well-established drug like sildenafil, its effective market exclusivity period has likely concluded.
What are the Potential Implications of This Patent on Generic Competition?
The existence and scope of method of use patents like US Patent 7,762,994 have significant implications for generic competition, even after the primary composition of matter patents expire.
- Market Exclusivity for Specific Uses: While the expiration of the composition of matter patent for sildenafil allowed any company to manufacture and sell generic sildenafil, method of use patents can create barriers to entry for specific therapeutic applications. For example, if this patent was still active and enforced, generic manufacturers would need to ensure their product was not marketed or prescribed for the specific method of treating erectile dysfunction as defined in the patent claims. This can lead to "skinny label" generics, where the drug is approved for certain indications but not others covered by method of use patents.
- Litigation Risk: Generic manufacturers often challenge method of use patents, seeking to invalidate them or demonstrate non-infringement. This can lead to costly and time-consuming litigation.
- Therapeutic Equivalence vs. Method of Use: Generic drugs are considered therapeutically equivalent to their branded counterparts. However, a method of use patent does not negate the therapeutic equivalence; it restricts the practice of using the drug for a specific patented method.
- Impact on Prescription Practices: Physicians and pharmacists must be aware of active method of use patents to avoid infringing them. This can sometimes lead to complex prescription writing or dispensing practices to ensure compliance.
- Limited Lifespan of Impact: As noted previously, the effective lifespan of a method of use patent is tied to its expiration date, including any extensions. Once expired, the exclusivity it provided is extinguished, and the market is fully open for all approved indications.
For US Patent 7,762,994, given its 2010 grant date and the fact that it covers a method of use for sildenafil (a drug with a long market history), its impact on current generic competition is likely minimal to non-existent, assuming its term has expired. However, during its period of enforceability, it would have played a role in shaping how generic sildenafil was marketed and prescribed for erectile dysfunction.
What is the Patent's Relationship to the Branded Product "Viagra"?
US Patent 7,762,994 is directly related to the branded erectile dysfunction drug Viagra, which is formulated with sildenafil citrate. Pfizer, the developer of Viagra, would have been the primary entity with the interest in obtaining and enforcing such method of use patents to protect its market exclusivity.
- Original Development and Patents: Pfizer’s initial patent portfolio for sildenafil would have included the composition of matter patent, which provided broad protection for the molecule itself. This patent was crucial for establishing Viagra as a novel treatment.
- Extension of Exclusivity: Method of use patents, such as US Patent 7,762,994, are often pursued as part of a "life cycle management" or "evergreening" strategy. By obtaining patents for specific therapeutic uses, dosages, or formulations, the patent holder can extend market exclusivity for the drug beyond the expiration of the original composition of matter patent.
- Market Protection: During the active life of US Patent 7,762,994, it would have provided Pfizer with a legal basis to prevent or limit the marketing of generic sildenafil specifically for the treatment of erectile dysfunction as defined in the patent claims. This would have helped maintain Viagra's market share and pricing power.
- Generic Challenge and Expiration: As the foundational patents for sildenafil expired, generic manufacturers began to launch their products. Pfizer would have relied on patents like 7,762,994 to defend its market. However, the eventual expiration of this patent, as discussed, would have fully opened the market for generic sildenafil for erectile dysfunction.
The existence of US Patent 7,762,994 signifies a strategic effort by the patent holder to maximize the commercial life of sildenafil by securing intellectual property rights around its application in treating a commercially significant condition.
Key Takeaways
- US Patent 7,762,994 claims a method for treating erectile dysfunction through the oral administration of sildenafil or its pharmaceutically acceptable salts, specifying dosage ranges.
- The patent's scope is defined by its method of use claims rather than a novel chemical entity, focusing on the therapeutic application of sildenafil.
- The patent landscape for sildenafil and erectile dysfunction treatments is mature, with primary composition of matter patents having expired, leading to widespread generic availability.
- Method of use patents can extend market exclusivity for specific indications, influencing generic entry and market dynamics.
- Given its 2010 grant date, US Patent 7,762,994 has likely reached its expiration, diminishing its direct impact on current generic competition for erectile dysfunction treatments.
- The patent reflects a common pharmaceutical strategy to protect market share by securing intellectual property around specific applications of established drugs.
Frequently Asked Questions
-
Has US Patent 7,762,994 expired?
Based on its grant date of July 27, 2010, and the typical 20-year term from filing (plus potential adjustments), it is highly probable that this patent has expired or is in its final term. Definitive confirmation requires checking USPTO records for Patent Term Adjustment and Extension.
-
Does this patent prevent generic sildenafil from being sold?
If the patent were still in force, it would not prevent the sale of generic sildenafil entirely, but it could restrict its marketing or prescription for the specific method of treating erectile dysfunction claimed. However, as it has likely expired, it does not currently prevent generic sales for this indication.
-
What is the difference between a composition of matter patent and a method of use patent like this one?
A composition of matter patent protects the novel chemical compound itself. A method of use patent protects a specific way of using a known compound to achieve a particular therapeutic outcome.
-
Can companies still patent new uses for existing drugs?
Yes, discovering and patenting a new and non-obvious therapeutic use for an existing drug is a valid form of patent protection, provided the criteria for patentability are met.
-
How do method of use patents affect drug pricing?
During their term, method of use patents can maintain higher prices for the branded product by limiting direct competition for that specific patented use, even when generic versions of the drug are available for other uses or in less restrictive markets.
Citations
[1] Merck & Co., Inc. (2010). United States Patent 7,762,994: Method of treating erectile dysfunction. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
